Peer-reviewed article
Seroefficacy of a 10-valent pneumococcal conjugate vaccine (Pneumosil®) compared with other pneumococcal conjugate vaccines in children.
Oluwasefunmi Akeju, Shuo Feng, Ed Clarke, Adedapo O Bashorun, Ikechukwu Adigweme et al. ·
Summary
Written by AI, not yet AICS's view · claude-haiku-4-5-20251001This study compared how well three pneumococcal vaccines protect children by measuring immune responses in 716 infants from two randomised trials. A new 10-valent vaccine (PCV10SII) showed similar protection to another 10-valent vaccine (PCV10GSK) against most pneumococcal types, but better protection against types 6A and 19A. When compared to a 13-valent vaccine (PCV13), PCV10SII provided better protection against type 14 but weaker protection against types 6A and 6B. The choice between these vaccines may depend on which pneumococcal types are most common in each country.
Key points
- PCV10SII showed no difference in seroinfection risk compared with PCV10GSK for shared serotypes
- PCV10SII offered better protection against serotypes 6A and 19A, which are not covered by PCV10GSK
- Compared with PCV13, PCV10SII had 65% lower risk of seroinfection for serotype 14
- PCV10SII showed 2.3 to 2.9-fold higher risk of seroinfection for serotypes 6A and 6B compared with PCV13
- Serotype-specific differences should be considered when choosing vaccines based on local disease patterns and cost-effectiveness
Limitations
The study measures immune response (seroinfection) as a proxy for protection but does not directly measure actual disease prevention or clinical outcomes in vaccinated children. The analysis is based on post-vaccination serotype-specific antibody levels and does not provide long-term follow-up data on actual pneumococcal disease incidence.
Abstract
BACKGROUND: A new 10-valent pneumococcal conjugate vaccine (PCV10SII) was prequalified by WHO in 2019 for children based on non-inferiority of immunogenicity to PCV13 and PCV10GSK. However, the efficacy of PCV10SII against pneumococcal carriage or disease has not been compared with other PCVs. We compared the risk of seroinfection in PCV10SII with PCV10GSK and PCV13-vaccinated infants. METHODS: Data were available for 716 infants from two randomised trials comparing the immunogenicity of PCV10SII with PCV13 and PCV10GSK. Serotype-specific IgG levels were measured from serum samples collected at four weeks after the primary vaccination series and at the time of booster vaccination. We defined seroinfection as any increase in serotype-specific IgG between post-primary vaccination and the booster dose, indicating likely colonisation, subclinical infection, or disease. We compared the relative risk (RR) of seroinfection between PCVs. RESULTS: There was no difference in the risk of seroinfection between PCV10SII and PCV10GSK for the shared serotypes, but PCV10SII showed better protection against 6A and 19A, not included in PCV10GSK. Compared with PCV13, the risk of seroinfection was 65% lower in PCV10SII for serotype 14 (RR = 0.35, 95% CI: 0.22, 0.57), 2.27-fold (95% CI: 1.40, 3.68) and 2.91-fold (95% CI: 1.84, 4.60) higher for 6A and 6B seroinfection, and similar for the remaining serotypes. CONCLUSION: PCV10SII demonstrated comparable seroefficacy as PCV10GSK against colonisation by serotypes common to both and may offer better coverage in countries with high prevalence of 6A and 19A disease. The serotype-specific differences in seroefficacy between PCV10SII and PCV13 should be considered when evaluating cost effectiveness. Funding Gates Foundation (INV-056261_2023).
Findings the Hub has extracted
Each claim below is labelled by its type of design and links back to this report.
- Intervention
- Vaccination with 10-valent pneumococcal conjugate vaccine (PCV10SII) compared with 10-valent (PCV10GSK) and 13-valent (PCV13) pneumococcal conjugate vaccines
- Population
- 716 infants from two randomised trials comparing PCV10SII, PCV10GSK, and PCV13
Key finding
No difference in seroinfection risk between PCV10SII and PCV10GSK for shared serotypes
Akeju et al. · PubMed (US National Library of Medicine) · 12 Aug 2026